# US 2025/0122549 A1 · Influenza virus hemagglutinin mutants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0122549 A1
- Document ID: US20250122549A1
- Status: Published application
- Kind: A1
- Application number: 18/909,318
- Filed: 2024-10-08
- Published: 2025-04-17
- Earliest claimed: 2018-06-27
- Assignees: Aramis Biotechnologies Inc.
- Applicants: Aramis Biotechnologies Inc.
- Inventors: Pierre-Olivier LAVOIE; Aurelien LORIN; Alain DOUCET; Marc-Andre D'AOUST; Manon COUTURE
- Web page: https://patentgrep.com/patent/US20250122549A1

## CPC

- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- A61K 39/12: Viral antigens
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61P 31/16: for influenza or rhinoviruses
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C07K 14/11: Orthomyxoviridae, e.g. influenza virus
- C07K 16/10: RNA viruses
- C07K 16/108: Orthomyxoviridae (F), e.g. influenza virus
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/8257: {for the production of primary gene products, e.g. pharmaceutical products, interferon}
- C12N 15/8258: {for the production of oral vaccines (antigens) or immunoglobulins}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/5258: {Virus-like particles}
- C12N 2760/16023: Virus like particles [VLP]
- C12N 2760/16033: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16123: Virus like particles [VLP]
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16152: relating to complementing cells and packaging systems for producing virus or viral particles
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to the production of modified influenza viral proteins in plants. More specifically, the present invention relates to producing and increasing influenza virus-like particle (VLP) production in plants, wherein the VLPs comprise the modified influenza viral proteins, such as modified influenza hemagglutinin (HA). The HA protein may comprising an amino acid sequence comprising at least one substitution when compared to a corresponding wildtype amino acid sequence. Further provided are nucleic acid encoding the modified HA protein. Furthermore methods of producing an influenza virus like particle (VLP) and methods of increasing yield of production of an influenza virus like particle (VLP) in a plant, portion of a plant, or a plant cell, are also provided.

## Claims

### Claim 1

A modified influenza H3 hemagglutinin (HA) protein comprising an amino acid sequence of a wildtype influenza H3 HA protein and comprising at least one amino acid substitution, said at least one amino acid substitution consisting of an amino acid substitution corresponding to position 382 of reference sequence SEQ ID NO: 92, and optionally one or more amino acid substitution corresponding to positions 384, 392 and/or 431 of reference sequence SEQ ID NO: 92, wherein:
the amino acid substitution corresponding to position 382 of reference sequence SEQ ID NO: 92 is to an alanine or a conserved substitution of alanine;
the amino acid substitution corresponding to position 384 of reference sequence SEQ ID NO: 92 is to a valine or a conserved substitution of valine;
the amino acid substitution corresponding to position 392 of reference sequence SEQ ID NO: 92 is to an aspartic acid or a conserved substitution of aspartic acid; and
the amino acid substitution corresponding to position 431 of reference sequence SEQ ID NO: 92 is to a methionine or a conserved substitution of methionine.

### Claim 2 (depends on 1)

The modified influenza H3 HA of claim 1, wherein:
the conserved substitution of alanine is serine, glycine, threonine, cysteine, or valine;
the conserved substitution of valine is isoleucine, methionine, alanine, or threonine;
the conserved substitution of aspartic acid is glutamic acid, glutamine, or serine; and/or
the conserved substitution of methionine is isoleucine, glutamine, valine or phenylalanine.

### Claim 3 (depends on 1)

The modified influenza H3 HA protein of claim 1, wherein the HA protein comprising an amino acid substitution corresponding to position 382 of reference sequence SEQ ID NO: 92, wherein the amino acid substitution is to alanine or a conserved substitution of alanine.

### Claim 4 (depends on 3)

The modified influenza H3 HA protein of claim 3, wherein the conserved substitution of alanine is serine, glycine, threonine, cysteine, or valine.

### Claim 5 (depends on 1)

The modified influenza H3 HA protein of claim 1, wherein the HA protein comprising an amino acid substitution corresponding to position 384 of reference sequence SEQ ID NO: 92, wherein the amino acid substitution is to valine or a conserved substitution of valine.

### Claim 6 (depends on 5)

The modified influenza H3 HA protein of claim 5, wherein the conserved substitution of valine is isoleucine, methionine, alanine, or threonine.

### Claim 7 (depends on 1)

The modified influenza H3 HA protein of claim 1, wherein the HA protein comprising an amino acid substitution corresponding to positions 382 and 384 of reference sequence SEQ ID NO: 92, wherein the amino acid substitution corresponding to position 382 of reference sequence SEQ ID NO: 92 is to alanine or a conserved substitution of alanine and the amino acid substitution corresponding to position 384 of reference sequence SEQ ID NO: 92 is to valine or a conserved substitution of valine.

### Claim 8 (depends on 7)

The modified influenza H3 HA protein of claim 7, wherein the conserved substitution of alanine is serine, glycine, threonine, cysteine, or valine, and the conserved substitution of valine is isoleucine, methionine, alanine, or threonine.

### Claim 9 (depends on 1)

The modified influenza H3 HA protein of claim 1, wherein the HA protein comprising an amino acid substitution corresponding to positions 382, 384 and 392 of reference sequence SEQ ID NO: 92, wherein:
the amino acid substitution corresponding to position 382 of reference sequence SEQ ID NO: 92 is to alanine or a conserved substitution of alanine;
the amino acid substitution corresponding to position 384 of reference sequence SEQ ID NO: 92 is to valine or a conserved substitution of valine; and
the amino acid substitution corresponding to position 392 of reference sequence SEQ ID NO: 92 is to an aspartic acid or a conserved substitution of aspartic acid.

### Claim 10 (depends on 9)

The modified influenza H3 HA protein of claim 9, wherein
the conserved substitution of alanine is serine, glycine, threonine, cysteine, or valine;
the conserved substitution of valine is isoleucine, methionine, alanine, or threonine; and
the conserved substitution of aspartic acid is glutamic acid, glutamine or serine.

### Claim 11 (depends on 1)

The modified influenza H3 HA protein of claim 1, wherein the HA protein comprising an amino acid substitution corresponding to position 382, 384 and 431 of reference sequence SEQ ID NO: 92, wherein:
the amino acid substitution corresponding to position 382 of reference sequence SEQ ID NO: 92 is to alanine or a conserved substitution of alanine;
the amino acid substitution corresponding to position 384 of reference sequence SEQ ID NO: 92 is to valine or a conserved substitution of valine; and
the amino acid substitution corresponding to position 431 of reference sequence SEQ ID NO: 92 is to a methionine or a conserved substitution of methionine.

### Claim 12 (depends on 11)

The modified influenza H3 HA protein of claim 11, wherein:
the conserved substitution of alanine is serine, glycine, threonine, cysteine, or valine;
the conserved substitution of valine is isoleucine, methionine, alanine, or threonine; and
the conserved substitution of methionine is isoleucine, glutamine, valine or phenylalanine.

### Claim 13 (depends on 1)

The modified influenza H3 HA protein of claim 1, wherein the HA protein comprising an amino acid substitution corresponding to positions 382, 384, 392 and 431 of reference sequence SEQ ID NO: 92, wherein:
the amino acid substitution corresponding to position 382 of reference sequence SEQ ID NO: 92 is to alanine or a conserved substitution of alanine;
the amino acid substitution corresponding to position 384 of reference sequence SEQ ID NO: 92 is to valine or a conserved substitution of valine;
the amino acid substitution corresponding to position 392 of reference sequence SEQ ID NO: 92 is to an aspartic acid or a conserved substitution of aspartic acid; and
the amino acid substitution corresponding to position 431 of reference sequence SEQ ID NO: 92 is to a methionine or a conserved substitution of methionine.

### Claim 14 (depends on 13)

The modified influenza H3 HA protein of claim 13, wherein
the conserved substitution of alanine is serine, glycine, threonine, cysteine, or valine;
the conserved substitution of valine is isoleucine, methionine, alanine, or threonine;
the conserved substitution of aspartic acid is glutamic acid, glutamine or serine; and
the conserved substitution of methionine is isoleucine, glutamine, valine or phenylalanine.

### Claim 15 (depends on 1)

A virus-like particle (VLP) comprising the modified influenza H3 hemagglutinin (HA) protein of claim 1.

### Claim 16 (depends on 3)

A virus-like particle (VLP) comprising the modified influenza H3 hemagglutinin (HA) protein of claim 3.

### Claim 17 (depends on 5)

A virus-like particle (VLP) comprising the modified influenza H3 hemagglutinin (HA) protein of claim 5.

### Claim 18 (depends on 7)

A virus-like particle (VLP) comprising the modified influenza H3 hemagglutinin (HA) protein of claim 7.

### Claim 19 (depends on 9)

A virus-like particle (VLP) comprising the modified influenza H3 hemagglutinin (HA) protein of claim 9.

### Claim 20 (depends on 11)

A virus-like particle (VLP) comprising the modified influenza H3 hemagglutinin (HA) protein of claim 11.

### Claim 21 (depends on 13)

A virus-like particle (VLP) comprising the modified influenza H3 hemagglutinin (HA) protein of claim 13.
